(CercleFinance.com) – Sanofi announces late-breaking Phase III data presented at the 2022 AAAAI Annual Meeting showing that Dupixent (dupilumab) significantly improves the signs and symptoms of eosinophilic esophagitis at 24 weeks, in patients 12 years and older.
‘Eosinophilic esophagitis is a chronic and progressive disease bearing a type 2 inflammatory signature which alters the esophagus and its functioning’, recalls the French pharmaceutical giant.
The data continue to support Dupixent’s well-established safety profile. Data from the clinical trial program has been submitted to the US FDA, with regulatory submissions in other countries also expected in 2022.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
